| Citation: |
LU Chaofan, LENG Xiaomei. Advances in the Drugs Treatment of Psoriatic Arthritis[J]. Medical Journal of Peking Union Medical College Hospital, 2025, 16(1): 65-74. DOI: 10.12290/xhyxzz.2024-0820
|
Psoriatic arthritis (PsA), an inflammatory articular disease closely associated with psoriasis, is characterized by a wide range of symptoms including skin lesion, peripheral and axial joint involvement, enthesitis, and dactylitis. In recent years, significant advancements have been made in the treatment of PsA, promoting continuous improvement in patient outcomes. This article aims to comprehensively review the current status of drug treatment for PsA, encompassing not only new clinical evidence for conventional synthetic disease-modifying antirheumatic drugs(csDMARDs) but also an in-depth exploration of biologics or targeted synthetic disease-modifying antirheumatic drugs(tsDMARDs) against various targets in recent years. The objective of this study is to enhance clinicians' understanding of treatment strategies for PsA and provide more precise and effective treatment options for patients.
| [1] |
Gossec L, Kerschbaumer A, Ferreira R J O, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update[J]. Ann Rheum Dis, 2024, 83(6): 706-719. DOI: 10.1136/ard-2024-225531
|
| [2] |
Singh J A, Guyatt G, Ogdie A, et al. Special article: 2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis[J]. Arthritis Care Res (Hoboken), 2019, 71(1): 2-29. DOI: 10.1002/acr.23789
|
| [3] |
Maese J, Díaz Del Campo P, Seoane-Mato D, et al. Effectiveness of conventional disease-modifying antirheumatic drugs in psoriatic arthritis: a systematic review[J]. Reumatol Clin (Engl Ed), 2018, 14(2): 81-89. DOI: 10.1016/j.reuma.2016.10.005
|
| [4] |
Kingsley G H, Kowalczyk A, Taylor H, et al. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis[J]. Rheumatology (Oxford), 2012, 51(8): 1368-1377. DOI: 10.1093/rheumatology/kes001
|
| [5] |
Coates L C, Helliwell P S. Methotrexate efficacy in the tight control in psoriatic arthritis study[J]. J Rheumatol, 2016, 43(2): 356-361. DOI: 10.3899/jrheum.150614
|
| [6] |
Mease P J, Gladman D D, Collier D H, et al. Etanercept and methotrexate as monotherapy or in combination for psoriatic arthritis: primary results from a randomized, controlled phase Ⅲ trial[J]. Arthritis Rheumatol, 2019, 71(7): 1112-1124. DOI: 10.1002/art.40851
|
| [7] |
van Mens L J J, de Jong H M, Fluri I, et al. Achieving remission in psoriatic arthritis by early initiation of TNF inhibition: a double-blind, randomised, placebo-controlled trial of golimumab plus methotrexate versus placebo plus methotrexate[J]. Ann Rheum Dis, 2019, 78(5): 610-616. DOI: 10.1136/annrheumdis-2018-214746
|
| [8] |
Clegg D O, Reda D J, Mejias E, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A department of veterans affairs cooperative study[J]. Arthritis Rheum, 1996, 39(12): 2013-2020. DOI: 10.1002/art.1780391210
|
| [9] |
Kaltwasser J P, Nash P, Gladman D, et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial[J]. Arthritis Rheum, 2004, 50(6): 1939-1950. DOI: 10.1002/art.20253
|
| [10] |
Jacobs M E, Pouw J N, Welsing P, et al. First-line csDMARD monotherapy drug retention in psoriatic arthritis: methotrexate outperforms sulfasalazine[J]. Rheumatology (Oxford), 2021, 60(2): 780-784. DOI: 10.1093/rheumatology/keaa399
|
| [11] |
Mulder M L M, Vriezekolk J E, Van Hal T W, et al. Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis (COMPLETE-PsA): a double-blind, placebo-controlled, randomised, trial[J]. Lancet Rheumatol, 2022, 4(4): e252-e261. DOI: 10.1016/S2665-9913(22)00028-5
|
| [12] |
Mease P J, Reddy S, Ross S, et al. Evaluating the efficacy of biologics with and without methotrexate in the treatment of psoriatic arthritis: a network meta-analysis[J]. RMD Open, 2024, 10(1): e003423. DOI: 10.1136/rmdopen-2023-003423
|
| [13] |
D'Angelo S, Cantini F, Ramonda R, et al. Effectiveness of adalimumab for the treatment of psoriatic arthritis: an Italian real-life retrospective study[J]. Front Pharmacol, 2019, 10: 1497. DOI: 10.3389/fphar.2019.01497
|
| [14] |
Mease P J, Gladman D D, Ritchlin C T, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial[J]. Arthritis Rheum, 2005, 52(10): 3279-3289. DOI: 10.1002/art.21306
|
| [15] |
Mease P J, Kivitz A J, Burch F X, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression[J]. Arthritis Rheum, 2004, 50(7): 2264-2272. DOI: 10.1002/art.20335
|
| [16] |
Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study[J]. Arthritis Rheum, 2009, 60(4): 976-986. DOI: 10.1002/art.24403
|
| [17] |
Mease P J, Fleischmann R, Deodhar A A, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)[J]. Ann Rheum Dis, 2014, 73(1): 48-55. DOI: 10.1136/annrheumdis-2013-203696
|
| [18] |
Sundanum S, Orr C, Veale D. Targeted therapies in psoriatic arthritis-an update[J]. Int J Mol Sci, 2023, 24(7): 6384. DOI: 10.3390/ijms24076384
|
| [19] |
Burmester G R, Panaccione R, Gordon K B, et al. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease[J]. Ann Rheum Dis, 2013, 72(4): 517-524. DOI: 10.1136/annrheumdis-2011-201244
|
| [20] |
Antoni C, Krueger G G, De Vlam K, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial[J]. Ann Rheum Dis, 2005, 64(8): 1150-1157. DOI: 10.1136/ard.2004.032268
|
| [21] |
Chimenti M S, Conigliaro P, Caso F, et al. Long-term effectiveness and drug survival of golimumab in patients affected by psoriatic arthritis with cutaneous involvement[J]. Clin Rheumatol, 2022, 41(1): 75-84. DOI: 10.1007/s10067-021-05874-6
|
| [22] |
Kavanaugh A, McInnes I B, Mease P, et al. Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study)[J]. Ann Rheum Dis, 2014, 73(9): 1689-1694. DOI: 10.1136/annrheumdis-2013-204902
|
| [23] |
Esposito M, Carubbi F, Giunta A, et al. Certolizumab pegol for the treatment of psoriatic arthritis and plaque psoriasis[J]. Expert Rev Clin Immunol, 2020, 16(2): 119-128. DOI: 10.1080/1744666X.2020.1713754
|
| [24] |
Baranauskaite A, Raffayová H, Kungurov N V, et al. Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study[J]. Ann Rheum Dis, 2012, 71(4): 541-548. DOI: 10.1136/ard.2011.152223
|
| [25] |
Kavanaugh A, Husni M E, Harrison D D, et al. Safety and efficacy of intravenous golimumab in patients with active psoriatic arthritis: results through week twenty-four of the GO-VIBRANT study[J]. Arthritis Rheumatol, 2017, 69(11): 2151-2161. DOI: 10.1002/art.40226
|
| [26] |
Mease P, Deodhar A, Fleischmann R, et al. Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure[J]. RMD Open, 2015, 1(1): e000119. DOI: 10.1136/rmdopen-2015-000119
|
| [27] |
Curry P D K, Hum R M, Morris A P, et al. Non-trough serum drug levels of adalimumab and etanercept are associated with response in patients with psoriatic arthritis[J/OL ]. Rheumatology (Oxford): kead666. [2024-10-15]. https://doi.org/10.1093/rheumatology/kead666.
|
| [28] |
Hellamand P, Van De Sande M G H, Ørnbjerg L M, et al. Sex differences in the effectiveness of first-line tumor necrosis factor inhibitors in psoriatic arthritis: results from the European spondyloarthritis research collaboration network[J]. Arthritis Rheumatol, 2024, 76(4): 587-598. DOI: 10.1002/art.42758
|
| [29] |
Iwakura Y, Nakae S, Saijo S, et al. The roles of IL-17A in inflammatory immune responses and host defense against pathogens[J]. Immunol Rev, 2008, 226: 57-79. DOI: 10.1111/j.1600-065X.2008.00699.x
|
| [30] |
Miossec P, Korn T, Kuchroo V K. Interleukin-17 and type 17 helper T cells[J]. N Engl J Med, 2009, 361(9): 888-898. DOI: 10.1056/NEJMra0707449
|
| [31] |
McInnes I B, Kavanaugh A, Gottlieb A B, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial[J]. Lancet, 2013, 382(9894): 780-789. DOI: 10.1016/S0140-6736(13)60594-2
|
| [32] |
Ritchlin C, Rahman P, Kavanaugh A, et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial[J]. Ann Rheum Dis, 2014, 73(6): 990-999. DOI: 10.1136/annrheumdis-2013-204655
|
| [33] |
Gossec L, Siebert S, Bergmans P, et al. Long-term effectiveness and persistence of ustekinumab and TNF inhibitors in patients with psoriatic arthritis: final 3-year results from the PsABio real-world study[J]. Ann Rheum Dis, 2023, 82(4): 496-506. DOI: 10.1136/ard-2022-222879
|
| [34] |
Deodhar A, Helliwell P S, Boehncke W H, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial[J]. Lancet, 2020, 395(10230): 1115-1125. DOI: 10.1016/S0140-6736(20)30265-8
|
| [35] |
Mease P J, Rahman P, Gottlieb A B, et al. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial[J]. Lancet, 2020, 395(10230): 1126-1136. DOI: 10.1016/S0140-6736(20)30263-4
|
| [36] |
Ritchlin C T, Helliwell P S, Boehncke W H, et al. Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase Ⅲ randomised study of patients who were biologic-naïve or TNFα inhibitor-experienced[J]. RMD Open, 2021, 7(1): e001457. DOI: 10.1136/rmdopen-2020-001457
|
| [37] |
McInnes I B, Rahman P, Gottlieb A B, et al. Efficacy and safety of guselkumab, an interleukin-23p19-specific monoclonal antibody, through one year in biologic-naive patients with psoriatic arthritis[J]. Arthritis Rheumatol, 2021, 73(4): 604-616. DOI: 10.1002/art.41553
|
| [38] |
Curtis J R, Deodhar A, Soriano E R, et al. Early improvements with guselkumab associate with sustained control of psoriatic arthritis: post hoc analyses of two phase 3 trials[J]. Rheumatol Ther, 2024, 11(6): 1501-1517. DOI: 10.1007/s40744-024-00702-0
|
| [39] |
Kristensen L E, Keiserman M, Papp K, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial[J]. Ann Rheum Dis, 2022, 81(2): 225-231. DOI: 10.1136/annrheumdis-2021-221019
|
| [40] |
Östör A, Van Den Bosch F, Papp K, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial[J]. Ann Rheum Dis, 2022, 81(3): 351-358. DOI: 10.1136/annrheumdis-2021-221048
|
| [41] |
Kristensen L E, Keiserman M, Papp K, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 1 study[J]. Rheumatology (Oxford), 2023, 62(6): 2113-2121. DOI: 10.1093/rheumatology/keac607
|
| [42] |
Östör A, Van Den Bosch F, Papp K, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 2 study[J]. Rheumatology (Oxford), 2023, 62(6): 2122-2129. DOI: 10.1093/rheumatology/keac605
|
| [43] |
Kavanaugh A, Puig L, Gottlieb A B, et al. Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase Ⅲ, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2)[J]. Ann Rheum Dis, 2016, 75(11): 1984-1988. DOI: 10.1136/annrheumdis-2015-209068
|
| [44] |
Helliwell P S, Gladman D D, Chakravarty S D, et al. Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials[J]. RMD Open, 2020, 6(1): e001149. DOI: 10.1136/rmdopen-2019-001149
|
| [45] |
Blauvelt A, Chiricozzi A. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis[J]. Clin Rev Allergy Immunol, 2018, 55(3): 379-390. DOI: 10.1007/s12016-018-8702-3
|
| [46] |
Kivitz A J, Kremer J M, Legerton C W 3rd, et al. Efficacy and safety of secukinumab in US patients with psoriatic arthritis: a subgroup analysis of the phase 3 FUTURE studies[J]. Rheumatol Ther, 2024, 11(3): 675-689. DOI: 10.1007/s40744-024-00666-1
|
| [47] |
Alegre-Sancho J J, Núñez-Monje V, Campos-Fernández C, et al. Real-world effectiveness and persistence of secukinu-mab in the treatment of patients with psoriatic arthritis[J]. Front Med (Lausanne), 2023, 10: 1294247.
|
| [48] |
Mease P J, Landewé R, Rahman P, et al. Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) results from the FUTURE 5 study[J]. RMD Open, 2021, 7(2): e001600. DOI: 10.1136/rmdopen-2021-001600
|
| [49] |
Russo F, Galluzzo M, Stingeni L, et al. Long-term drug survival and effectiveness of secukinumab in patients with moderate to severe chronic plaque psoriasis: 42-month results from the SUPREME 2.0 study[J]. Clin Cosmet Investig Dermatol, 2023, 16: 3561-3574. DOI: 10.2147/CCID.S416149
|
| [50] |
Gladman D D, Orbai A M, Klitz U, et al. Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis[J]. Arthritis Res Ther, 2019, 21(1): 38. DOI: 10.1186/s13075-019-1831-0
|
| [51] |
Lebwohl M G, Gordon K B, Gallo G, et al. Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER-3 study[J]. J Eur Acad Dermatol Venereol, 2020, 34(2): 301-309. DOI: 10.1111/jdv.15921
|
| [52] |
Deodhar A A, Combe B, Accioly A P, et al. Safety of ixekizumab in patients with psoriatic arthritis: data from four clinical trials with over 2000 patient-years of exposure[J]. Ann Rheum Dis, 2022, 81(7): 944-950. DOI: 10.1136/annrheumdis-2021-222027
|
| [53] |
Takami K, Tsuji S, Sato S, et al. Long-term retention rates of anti-tumour necrosis factor and anti-interleukin-17 antibodies for patients with psoriatic arthritis[J]. Mod Rheumatol, 2024, 34(5): 1013-1018. DOI: 10.1093/mr/road111
|
| [54] |
Facheris P, Valenti M, Pavia G, et al. Brodalumab: a new way to inhibit IL-17 in psoriasis[J]. Dermatol Ther, 2020, 33(3): e13403.
|
| [55] |
Mease P J, Helliwell P S, Hjuler K F, et al. Brodalumab in psoriatic arthritis: results from the randomised phase Ⅲ AMVISION-1 and AMVISION-2 trials[J]. Ann Rheum Dis, 2021, 80(2): 185-193. DOI: 10.1136/annrheumdis-2019-216835
|
| [56] |
Egeberg A, Andersen Y M F, Halling-Overgaard A S, et al. Systematic review on rapidity of onset of action for interleukin-17 and interleukin-23 inhibitors for psoriasis[J]. J Eur Acad Dermatol Venereol, 2020, 34(1): 39-46. DOI: 10.1111/jdv.15920
|
| [57] |
Kojanova M, Hugo J, Velackova B, et al. Efficacy, safety, and drug survival of patients with psoriasis treated with IL-17 inhibitors - brodalumab, ixekizumab, and secukinumab: real-world data from the Czech Republic BIOREP registry[J]. J Dermatolog Treat, 2022, 33(6): 2827-2837. DOI: 10.1080/09546634.2022.2082354
|
| [58] |
Ritchlin C T, Kavanaugh A, Merola J F, et al. Bimekizu-mab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial[J]. Lancet, 2020, 395(10222): 427-440. DOI: 10.1016/S0140-6736(19)33161-7
|
| [59] |
Mease P J, Warren R B, Nash P, et al. Comparative effectiveness of bimekizumab and secukinumab in patients with psoriatic arthritis at 52 weeks using a matching-adjusted indirect comparison[J]. Rheumatol Ther, 2024, 11(3): 817-828. DOI: 10.1007/s40744-024-00652-7
|
| [60] |
Mease P J, Gottlieb A B, Van Der Heijde D, et al. Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase Ⅲ study in psoriatic arthritis[J]. Ann Rheum Dis, 2017, 76(9): 1550-1558. DOI: 10.1136/annrheumdis-2016-210724
|
| [61] |
Mease P, Genovese M C, Gladstein G, et al. Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase Ⅱ trial[J]. Arthritis Rheum, 2011, 63(4): 939-948. DOI: 10.1002/art.30176
|
| [62] |
Østergaard M, Bird P, Pachai C, et al. Implementation of the OMERACT psoriatic arthritis magnetic resonance imaging scoring system in a randomized phase Ⅱb study of abatacept in psoriatic arthritis[J]. Rheumatology (Oxford), 2022, 61(11): 4305-4313. DOI: 10.1093/rheumatology/keac073
|
| [63] |
Mease P, Hall S, FitzGerald O, et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis[J]. N Engl J Med, 2017, 377(16): 1537-1550. DOI: 10.1056/NEJMoa1615975
|
| [64] |
McInnes I B, Anderson J K, Magrey M, et al. Trial of upadacitinib and adalimumab for psoriatic arthritis[J]. N Engl J Med, 2021, 384(13): 1227-1239. DOI: 10.1056/NEJMoa2022516
|
| [65] |
Mease P J, Lertratanakul A, Anderson J K, et al. Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2[J]. Ann Rheum Dis, 2021, 80(3): 312-320. DOI: 10.1136/annrheumdis-2020-218870
|
| [66] |
Fleischmann R, Pangan A L, Song I H, et al. Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase Ⅲ, double-blind, randomized controlled trial[J]. Arthritis Rheumatol, 2019, 71(11): 1788-1800. DOI: 10.1002/art.41032
|
| [67] |
Mease P, Coates L C, Helliwell P S, et al. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial[J]. Lancet, 2018, 392(10162): 2367-2377. DOI: 10.1016/S0140-6736(18)32483-8
|
| [68] |
Reinisch W, Hellstrom W, Dolhain R J E M, et al. Effects of filgotinib on semen parameters and sex hormones in male patients with inflammatory diseases: results from the phase 2, randomised, double-blind, placebo-controlled MANTA and MANTA-RAy studies[J]. Ann Rheum Dis, 2023, 82(8): 1049-1058. DOI: 10.1136/ard-2023-224017
|
| [69] |
Pelechas E, Kaltsonoudis E, Migkos M P, et al. State of the art review on the treatment of psoriatic disease[J]. Mediterr J Rheumatol, 2024, 35(1): 66-72. DOI: 10.31138/mjr.040123.sot
|
| [70] |
Ytterberg S R, Bhatt D L, Mikuls T R, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis[J]. N Engl J Med, 2022, 386(4): 316-326. DOI: 10.1056/NEJMoa2109927
|
| [71] |
Charles-Schoeman C, Buch M H, Dougados M, et al. Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance[J]. Ann Rheum Dis, 2023, 82(1): 119-129. DOI: 10.1136/ard-2022-222259
|
| [72] |
Charles-Schoeman C, DeMasi R, Valdez H, et al. Risk factors for major adverse cardiovascular events in phase Ⅲ and long-term extension studies of tofacitinib in patients with rheumatoid arthritis[J]. Arthritis Rheumatol, 2019, 71(9): 1450-1459. DOI: 10.1002/art.40911
|
| [73] |
Szekanecz Z, Giles J T, Buch M H, et al. POS0110 Incidence of major adverse cardiovascular events stratified by geographic region and baseline cardiovascular risk: a post hoc analysis of oral surveillance[J]. Ann Rheum Dis, 2022, 81(S1): 278-279.
|
| [74] |
Szekanecz Z, Buch M H, Charles-Schoeman C, et al. Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician[J]. Nat Rev Rheumatol, 2024, 20(2): 101-115. DOI: 10.1038/s41584-023-01062-9
|
| [75] |
Charles-Schoeman C, Fleischmann R, Mysler E, et al. Risk of venous thromboembolism with tofacitinib versus tumor necrosis factor inhibitors in cardiovascular risk-enriched rheumatoid arthritis patients[J]. Arthritis Rheumatol, 2024, 76(8): 1218-1229. DOI: 10.1002/art.42846
|
| [76] |
Mease P J, Deodhar A A, Van Der Heijde D, et al. Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase Ⅱ trial in psoriatic arthritis[J]. Ann Rheum Dis, 2022, 81(6): 815-822. DOI: 10.1136/annrheumdis-2021-221664
|
| [77] |
Mease P, Helliwell P, Silwinska-Stanczyk P, et al. Efficacy and safety of the TYK2/JAK1 inhibitor brepocitinib for active psoriatic arthritis: a phase Ⅱb randomized controlled trial[J]. Arthritis Rheumatol, 2023, 75(8): 1370-1380. DOI: 10.1002/art.42519
|
| [1] | WANG Jun, MENG Juan. Targeted Therapy for Rheumatoid Arthritis in the New Era[J]. Medical Journal of Peking Union Medical College Hospital, 2025, 16(1): 19-27. DOI: 10.12290/xhyxzz.2024-0842 |
| [2] | CUI Hanshu, LIU Bin. Controversy About Management of Osteoarthritis with Disease-modifying Anti-rheumatic Drugs[J]. Medical Journal of Peking Union Medical College Hospital, 2025, 16(1): 13-18. DOI: 10.12290/xhyxzz.2024-0802 |
| [3] | TIAN Kunling, CHEN Chuanning. Notch Signaling Pathway and Congenital Heart Disease[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(3): 649-654. DOI: 10.12290/xhyxzz.2023-0594 |
| [4] | YANG Xiaoxi, TIAN Xinping, LI Mengtao, LENG Xiaomei, ZHAO Yan, ZENG Xiaofeng. Interpretation on the Consensus on Targeted Drug Therapy for Spondyloarthritis[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(1): 58-67. DOI: 10.12290/xhyxzz.2023-0391 |
| [5] | ZHANG Lu, LI Jian. Castleman Disease in China: State-of-the-art Technology Before the Era of IL-6 Targeted Therapy[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(5): 911-914. DOI: 10.12290/xhyxzz.2023-0227 |
| [6] | SHEN Tian, WU Xiaochuan. Systemic Lupus Erythematosus: from Pathogenesis to New Targeted Therapies[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(2): 234-240. DOI: 10.12290/xhyxzz.2022-0694 |
| [7] | ZHAO Zhe, TANG Yan, ZHOU Jingya, CHEN Xiaoguang, ZHANG Lei, CHEN Limeng, YUAN Tao. Analysis of Clinical Manifestations and Drug Therapies of Gitelman Syndrome[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(2): 277-286. DOI: 10.12290/xhyxzz.2021-0180 |
| [8] | Hua-xia YANG, Feng-chun ZHANG. New Biologic Targets for Systemic Lupus Erythematosus: Hope and Challenge[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(3): 241-246. DOI: 10.3969/j.issn.1674-9081.20200091 |
| [9] | Feng-chun ZHANG. What do We Need to Know about Rheumatology[J]. Medical Journal of Peking Union Medical College Hospital, 2017, 8(4-5): 204-206. DOI: 10.3969/j.issn.1674-9081.2017.05.002 |
| [10] | Qing-jun WU, Zhang-han DAI, Wen ZHANG, Yong-zhe LI, Xin-ping TIAN, Xuan ZHANG, Yan ZHAO, Xiao-feng ZENG, Feng-chun ZHANG, Fu-lin TANG. Characteristics of Antisynthetase Syndrome with Anti-threonyl tRNA Synthetase Antibody[J]. Medical Journal of Peking Union Medical College Hospital, 2013, 4(1): 26-30. DOI: 10.3969/j.issn.1674-9081.2013.01.006 |
Supported by: Beijing Renhe Information Technology Co., Ltd. 
Submit
Review
Office
Email Alert
RSS
DownLoad: